The Moderna (MRNA) stock price rose today after the flu vaccine showed promising results in a phase three trial. Is Moderna no longer a one hit wonder that was associated with Covid-19? The healthcare company expects to release 15 new products over the next 5 years. George Tsilis weighs in on possible upcoming booster shots.